377 completed, 87 terminated, 79 recruiting, 56 unknown. 700 Phase 1, 199 Phase 2.
Follow Herpesviridae Infections: new trials by email Literature Review of Herpesviridae Infections trials Research Report on Herpesviridae Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-08-11 |
| Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies | Phase 1 | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2027-04-01 | 2026-10-20 |
| Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene Biopsy Procedure, Biospecimen Collection, Computed Tomography - Burkitt Lymphoma, Double-Expressor Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 50 | 2027-01-11 | 2026-10-14 |
| Study Of KITE-753 in R/R B-Cell ALL KITE-753 - B-cell Acute Lymphoblastic Leukemia | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 18 | 2026-12-31 | 2026-09-11 |
| Phase 1 Trial to Evaluate Safety and Immunogenicity of MVA-BN-EBV in Healthy Young Adults MVA-BN-EBV, Placebo - Epstein Barr Virus (EBV) Infection | Phase 1 | Not yet recruiting | Bavarian Nordic | 15 | 2026-12-15 | 2026-10-22 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
| Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia Rituximab - PTLD, Epstein Barr Virus (EBV) Infection | Phase 1 | Not yet recruiting | Jennifer Amengual | 28 | 2026-12-01 | 2026-09-17 |
| CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study MB-CART19.1 - Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Hospital Universitario Dr. Jose E. Gonzalez | 30 | 2026-12-01 | 2026-10-22 |
| mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults VXCO-102, Placebo - EBV | Phase 1 | Recruiting | Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company | 82 | 2026-11-16 | 2026-10-26 |
| Metabolically Fit CD19 CAR T Cells With CD34 Selection Markers in Adults With CD19-Positive B-Cell Acute Lymphocytic Leukemia Fludarabine, Cyclophosphamide, Levetiracetam - CD19 Positive, B-ALL | Phase 1 | Not yet recruiting | Medical University of South Carolina | 18 | 2026-11-01 | 2026-10-26 |
| EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases Donor-derived ex-vivo expanded EBV Tscm CTL - EBV Lymphoma, Post-transplant Lymphoproliferative Disease (PTLD) | Phase 1 / Phase 2 | Not yet recruiting | University Hospital, Basel, Switzerland | 10 | 2026-11-01 | 2025-03-03 |
| Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and Above Recombinant Zoster Vaccine (CHO cell) SYS6052, Placebo: 0.9% sodium chloride injection, Active Comparator Vaccine - Herpes Zoster | Phase 1 / Phase 2 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 496 | 2026-10-31 | 2026-10-23 |
| Pre-emptive Anakinra for Cytokine Event Reduction Anakinra (Kineret®) - B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy | Phase 1 / Phase 2 | Withdrawn | Kevin McNerney | 2026-10-01 | 2026-08-13 | |
| BLinatumomab and iNKT in Relapsed B-Cell ALL Invariant Natural Killer T Cell Therapy - B-Cell ALL, ALL (Acute B-Lymphoblastic Leukemia) | Phase 1 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 13 | 2026-10-01 | 2026-10-09 |
| A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia Blinatumomab Injection - B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult | Phase 1 / Phase 2 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 26 | 2026-09-01 | 2026-08-11 |
| Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma Biospecimen Collection, Pomalidomide - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Recruiting | University of Michigan Rogel Cancer Center | 12 | 2026-08-26 | 2026-10-15 |
| A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL) VK-2019 - Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B Cell Lymphoma Relapsed | Phase 1 | Recruiting | Pierluigi Porcu | 30 | 2026-08-21 | 2026-09-02 |
| GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia GN001 - Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital | 42 | 2026-08-04 | 2026-11-02 |
| Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections pathogen-specific CTLs - Pathogen Infection, EBV Infection | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2026-06-01 | 2026-11-02 |
| NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL Antigen-specific T cells CART/CTL and DCvac - B-Cell Acute Lymphoblastic Leukemia | Phase 1 | Terminated | Shenzhen Geno-Immune Medical Institute | 10 | 2026-06-01 | 2026-11-02 |
Showing 20 of 700. Sign in to see all of them.
Burkitt Lymphoma (436) · Lymphoma, Large B-Cell, Diffuse (256) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (252) · Lymphoma, Follicular (234) · Lymphoma, Mantle-Cell (234) · Lymphoma, Non-Hodgkin (230) · Leukemia, Lymphocytic, Chronic, B-Cell (212) · Lymphoma, B-Cell, Marginal Zone (208) · Lymphoma, Large-Cell, Immunoblastic (194) · Lymphoma (191) · Hodgkin Disease (155) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (118) · Lymphoma, Large-Cell, Anaplastic (112) · Lymphoma, T-Cell, Cutaneous (111) · Waldenstrom Macroglobulinemia (109)
DNA Virus Infections (699) · Infections (688) · Virus Diseases (687) · Immune System Diseases (512) · Tumor Virus Infections (495) · Neoplasms by Histologic Type (493) · Neoplasms (475) · Hemic and Lymphatic Diseases (459) · Immunoproliferative Disorders (457) · Lymphatic Diseases (457) · Lymphoproliferative Disorders (445) · Epstein-Barr Virus Infections (433) · Lymphoma, B-Cell (390) · Hematologic Diseases (322)
Cyclophosphamide (68) · Rituximab (37) · fludarabine phosphate (30) · Filgrastim (28) · Peripheral Blood Stem Cell Transplantation (28) · Etoposide (27) · Vincristine (25) · fludarabine (25) · Cytarabine (21) · Prednisone (21) · Methotrexate (16) · Doxorubicin (15) · blinatumomab (15) · Biopsy (14) · Cyclosporine (14)
National Cancer Institute (NCI) (89) · National Institute of Allergy and Infectious Diseases (NIAID) (39) · City of Hope Medical Center (19) · Fred Hutchinson Cancer Center (15) · Baylor College of Medicine (14) · M.D. Anderson Cancer Center (14) · Memorial Sloan Kettering Cancer Center (14) · GlaxoSmithKline (13) · National Institutes of Health Clinical Center (CC) (10) · Northwestern University (9) · Masonic Cancer Center, University of Minnesota (8) · Mayo Clinic (8) · Merck Sharp & Dohme LLC (8) · ModernaTX, Inc. (8) · Case Comprehensive Cancer Center (7)
United States (501) · China (74) · Canada (30) · United Kingdom (29) · Australia (24) · France (19) · Spain (16) · Italy (14) · Germany (13) · South Korea (12) · Belgium (10) · Japan (10) · Taiwan (7) · Netherlands (6) · Singapore (5)
Helen E Heslop, MD (6) · Ramya M Ramaswami, M.D. (5) · Ajay Gopal (4) · Kenneth G. Lucas, MD (4) · Roger Strair, MD, PhD (4) · Shivaani Kummar, MD (4) · Edward A. Sausville, MD, PhD (3) · Elias Jabbour, MD (3) · Gill PS (3) · Helen Heslop, MD (3) · Ibrahim Aldoss (3) · Jack D. Burton, MD (3)
PMID 34515338, PMID 41671463, PMID 35622074, PMID 37781954, PMID 19949018, PMID 20028764, PMID 22002018, PMID 32499241, PMID 33308471, PMID 34687939, PMID 34889384, PMID 37486616, PMID 40367950, PMID 42341322, PMID 10552943, PMID 10632319, PMID 10764422, PMID 11410496, PMID 11756154, PMID 12171484, PMID 14630685, PMID 14767498, PMID 15013589, PMID 15570084, PMID 16135477, PMID 17119113, PMID 17312328, PMID 17940609, PMID 17947483, PMID 17959855, PMID 18079362, PMID 18224669, PMID 18270560, PMID 18327587, PMID 18463792, PMID 18470481, PMID 18846389, PMID 18971421, PMID 18974373, PMID 19139736, PMID 19179301, PMID 19238148, PMID 19443656, PMID 19451403, PMID 19652067, PMID 19789320, PMID 19880495, PMID 20407240, PMID 21247755, PMID 21311578
P30CA033572 (14), U01CA097452 (9), P30CA015083 (7), U01CA121947 (7), U01CA062487 (6), U01CA062502 (6), U01CA069912 (6), 2023 (5), P30CA006973 (5), P30CA015704 (5), U01CA062491 (5), U01CA099168 (5), P30CA008748 (4), P30CA016058 (4), P30CA016672 (4)